+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Doxorubicin Market Report by Application (Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Endometrial Cancer, and Others), Distribution Channel (Hospital and Retail Pharmacies, Online Stores, and Others), and Region 2024-2032

  • PDF Icon

    Report

  • 144 Pages
  • July 2024
  • Region: Global
  • IMARC Group
  • ID: 5633187
The global doxorubicin market size reached US$ 1.3 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 2.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2023-2032.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, Wilms’ tumor, non-Hodgkin’s lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

The report provides an analysis of the key trends in each sub-segment of the global doxorubicin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and distribution channel.

Breakup by Application:

Breast Cancer
Ovarian Cancer
Multiple Myeloma
Kaposi Sarcoma
Leukemia
Bone Sarcoma
Endometrial Cancer
Others

Breakup by Distribution Channel:

Hospital and Retail Pharmacies
Online Stores
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report:

How has the global doxorubicin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global doxorubicin market?
What are the key regional markets?
What is the breakup of the market based on the application?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global doxorubicin market and who are the key players?
What is the degree of competition in the industry?

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Doxorubicin Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Application
6.1 Breast Cancer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Ovarian Cancer
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Multiple Myeloma
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Kaposi Sarcoma
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Leukemia
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Bone Sarcoma
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Endometrial Cancer
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Others
6.8.1 Market Trends
6.8.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital and Retail Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Online Stores
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.2 Baxter International Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Cadila Pharmaceuticals
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.4 Cipla Inc.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Hikma Pharmaceuticals PLC
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.6 Meiji Holdings Co. Ltd.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Novartis AG
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Pfizer Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
List of Figures
Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
Figure 2: Global: Doxorubicin Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2023
Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2023
Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2023
Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: North America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: United States: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Canada: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: China: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Japan: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: India: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: Australia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Europe: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Germany: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: France: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Italy: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: Spain: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Russia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2023
Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Global: Doxorubicin Industry: SWOT Analysis
Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 5: Global: Doxorubicin Market: Competitive Structure
Table 6: Global: Doxorubicin Market: Key Players

Companies Mentioned

  • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
  • Baxter International Inc.
  • Cadila Pharmaceuticals
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Meiji Holdings Co. Ltd.
  • Novartis AG
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information